Rab Diagnostics specializes in biomarker development for oncology-focused Antibody-Drug Conjugates (ADCs). Through our proprietary RabCANCER platform and deep expertise in intracellular drug trafficking, we provide high-quality, mechanism-driven insights to accelerate drug development and enable precision medicine. We bridge the gap between preclinical discoveries and clinical implementation by developing robust research tools and diagnostic kits, translating insights into clinical solutions. Based on world class science at Oslo University Hospital and headquartered in Oslo, Norway, collaborative partnerships and scientific rigor are in our DNA. We support biopharmaceutical companies in delivering precise, effective cancer therapies to patients worldwide.